Gene correction of apolipoprotein (APO) E2 and APOE4 phenotypes to wild-type APOE3 by in situ chimeraplasty
Aristides D. Tagalakis(Edge Hill University), JS Owen(The Royal Free Hospital), David Riddell(Eli Lilly (United States)), George Dickson(Royal Holloway University of London), Ian R. Graham(Royal Holloway University of London)
Cited by 0
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351
Compartmentalization of β-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts
|Current Biology|2001|302
The LXR agonist TO901317 selectively lowers hippocampal Aβ42 and improves memory in the Tg2576 mouse model of Alzheimer's disease
|Molecular and Cellular Neuroscience|2007|248